Is Vitamin K1 Bone Turnover Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Vitamin K1 Bone Turnover Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Conclusion The data from this post-hoc analysis do not provide evidence for the assumption that vitamin K status modifies or enhances effects of vitamin D supplementation on cardiovascular or bone parameters. [Theiler-Schwetz V (2026); evidence level 2] - These findings are in line with current guidelines, which do not routinely recommend vitamin K and D co-treatment in patients with osteoporosis. [Theiler-Schwetz V (2026); evidence level 2] - Background/objectives Vitamin K and D co-treatment may have additive effects on bone and cardiovascular health and is frequently used as an over-the-counter supplement. [Theiler-Schwetz V (2026); evidence level 2] - The primary aim of this study was to assess whether the effect of vitamin D supplementation on bone turnover markers and cardiovascular parameters is modified according to vitamin K status at baseline (i.e., serum levels of vitamin K1, MK4 and MK7). [Theiler-Schwetz V (2026); evidence level 2] - Body weight was measured once a week, and the food efficiency ratio (FER) was calculated by dividing the increased body weight from day1 to the final day by the food intake amount during the experiment period. [Kim Misung (2013); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.